Massachusetts, USA (CU)_ Eirion Therapeutics, Inc., a Woburn-based aesthetic dermatology company in Massachusetts, announced its partnership with HTL Biotechnology, the world’s leading provider of biotechnology solutions based on hyaluronic acid and other biopolymers. According to the company, HTL will be Eirion’s manufacturer of the exclusive botulinum active pharmaceutical ingredient (API).
Botulinum is the active component of Eirion’s primary product candidate ET-01, which is a topical neuromodulator presently in Phase 2 clinical trials that is made for treating…
